2,616 United Therapeutics Corporation $UTHR Shares Acquired by Machina Capital S.A.S.

Machina Capital S.A.S. lifted its position in United Therapeutics Corporation (NASDAQ:UTHR) by 288.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,524 shares of the biotechnology company’s stock after acquiring an additional 2,616 shares during the quarter. Machina Capital S.A.S.’s holdings in United Therapeutics were worth $1,910,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in United Therapeutics in the 2nd quarter valued at $2,868,735,000. Jupiter Topco LLC purchased a new stake in shares of United Therapeutics during the second quarter valued at $450,140,000. Bank of New York Mellon Corp purchased a new stake in shares of United Therapeutics during the second quarter valued at $159,522,000. Caisse de depot et placement du Quebec bought a new position in shares of United Therapeutics in the second quarter worth about $154,304,000. Finally, Legal & General Group Plc bought a new position in shares of United Therapeutics in the second quarter worth about $112,209,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Trading Down 0.4%

UTHR opened at $593.31 on Friday. United Therapeutics Corporation has a 12-month low of $455.63 and a 12-month high of $614.23. The business’s fifty day simple moving average is $540.58 and its 200-day simple moving average is $535.80. The company has a market capitalization of $25.27 billion, a price-to-earnings ratio of 22.39, a PEG ratio of 3.99 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The firm had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. During the same quarter in the previous year, the firm earned $7.16 earnings per share. The business’s revenue was up 4.1% compared to the same quarter last year. On average, equities research analysts predict that United Therapeutics Corporation will post 24.90 EPS for the current year.

United Therapeutics declared that its board has initiated a share buyback plan on Thursday, October 22nd that allows the company to buy back $2 billion in shares. This buyback authorization allows the biotechnology company to buy up to 8.3% of its shares through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

Latest United Therapeutics News

Here’s some of the latest news about UTHR:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target. Its forecasts point to rising EPS, from $27.46 in FY2026 to $53.67 in FY2030, suggesting expectations for substantial longer-term earnings growth. HC Wainwright coverage article
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for about $5.64 million, reducing her direct stake by 2.84%; she still owns about 324,443 shares. Director Christopher Patusky also sold 1,210 shares for $701,800, a 36.12% reduction in his position. Insider selling can create a near-term sentiment overhang, although it does not by itself indicate a change in the company’s outlook. CEO sale report Director sale report

Insider Transactions at United Therapeutics

In other United Therapeutics news, CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $511.09, for a total transaction of $4,855,355.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $165,819,572.87. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders have sold 412,238 shares of company stock worth $220,975,006. 8.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

UTHR has been the topic of several recent analyst reports. UBS Group set a $725.00 price target on shares of United Therapeutics in a research note on Monday, October 19th. Jefferies Financial Group reissued a “buy” rating and issued a $728.00 price objective on shares of United Therapeutics in a research report on Wednesday, October 14th. HC Wainwright started coverage on shares of United Therapeutics in a research report on Monday. They set a “buy” rating and a $660.00 target price on the stock. Leerink Partners raised their target price on shares of United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a research report on Monday, October 19th. Finally, Morgan Stanley lifted their price target on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $676.40.

United Therapeutics Profile

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.